Gold-colored plasma is the liquid part of blood and represents about 55% of total blood volume. It contains essential proteins responsible for important life functions, such as immunity and blood coagulation.
Plasma-derived medicines are often the only possible treatment for many diseases. They include immunoglobulins for primary and secondary immunodeficiencies and autoimmune disorders, coagulation factors for bleeding disorders, and alpha-1 proteinase inhibitors to treat lung and liver disease.
Because plasma is a naturally occurring material – it’s in our body – patients depend on the generosity of healthy volunteer donors for plasma-derived therapies. Long production cycles including rigorous quality and safety checks can take up to a year from donation to manufacturing a medicine.
Large volumes are needed. As many as 1,200 donations are required to treat just one patient with hemophilia, a bleeding disorder, during a year.
Most plasma is obtained through a process known as plasmapheresis, a technique developed by Grifols in 1951 through which plasma is separated from the other blood components, which are then reinfused into the donor.
Quality and safety are our priorities in all steps, from the donor's arrival at the center through manufacturing and until the final product reaches patients.
Thousands of Egyptian patients are awaiting your plasma donations, which are essential for creating the high-quality medicines they need to live healthier, more productive lives.